2 citations
,
August 2013 in “The Lancet. Diabetes & endocrinology” The FDA rejected a testosterone drug again due to safety concerns.
July 2024 in “Reactions Weekly” 1 citations
,
August 2025 GLP-1 receptor agonists can help skin conditions but may cause hair loss and other skin issues.
February 2025 in “medRxiv (Cold Spring Harbor Laboratory)” GLP-1 agonists may increase the risk of hair loss.
January 2007 in “Zhōnghuá yàoxué zázhì” The method effectively showed that the two exemestane preparations are bioequivalent.
16 citations
,
February 2009 in “Clinical neurology and neurosurgery” Switching to extended-release divalproex sodium improved patient-reported tremor but did not change seizure frequency or most side effects.
February 2006 in “Inpharma Weekly” 31 citations
,
May 2017 in “JAAD Case Reports” ATX-101 injections can cause hair loss.
4 citations
,
August 2024 in “International Journal of Molecular Sciences” EBGS reduces platelet adhesion, potentially helping prevent blood clots.
2 citations
,
November 2024 in “AAPS PharmSciTech” Spanlastic formulations improve rivaroxaban's oral anticoagulation efficiency.
9 citations
,
July 2022 in “Journal of Clinical Oncology” Oral paclitaxel plus encequidar improved tumor response and caused less neuropathy but more serious infections than intravenous paclitaxel.
64 citations
,
August 2019 in “Circulation” ADT, especially enzalutamide, may increase the risk of heart rhythm problems and sudden death in men.
May 2023 in “Reactions Weekly” January 2013 in “Reactions Weekly”
A rash from semaglutide may be due to propylene glycol, not the drug itself.
35 citations
,
August 2004 in “Epilepsy & behavior” Extended-release divalproex is better tolerated and more effective for seizures and psychiatric symptoms than delayed-release divalproex, but doesn't reduce hair loss.
October 2025 in “Actualización en Medicina de Familia” New drugs face challenges due to limited evidence, and safety updates are advised for some existing medications.
3 citations
,
April 2021 in “Oncology Times” Trodelvy™ helped some patients with advanced breast cancer, but had side effects.
September 2024 in “Journal of the American Academy of Dermatology” Semaglutide does not significantly increase the risk of hair loss.
January 2026 in “RSC Advances” Epristeride's metabolism in zebrafish helps improve doping detection methods.
29 citations
,
September 2023 in “Journal of Clinical Medicine” Semaglutide helps obese PCOS patients lose weight and improve health.
October 2025 in “Figshare” Deuruxolitinib improves hair regrowth in alopecia areata but needs more safety research.
The FDA did not approve a testosterone drug because of safety concerns.
February 2025 in “Skin Appendage Disorders” GLP-1 receptor agonists can cause skin reactions, facial fat loss, and hair loss, but may help with wound healing and skin conditions.
October 2025 in “Figshare” Deuruxolitinib effectively treats alopecia areata but may cause manageable side effects.
September 2025 in “Journal of the American Academy of Dermatology” Deuruxolitinib significantly improves hair satisfaction in severe alopecia areata patients.
15 citations
,
June 2018 in “Life Sciences” Diabetex improves diabetic wound healing better than metformin.
1 citations
,
April 2023 in “Heliyon” Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.
7 citations
,
March 2011 in “Expert Opinion on Drug Safety” Exemestane is effective and safe for treating certain breast cancers, with mild side effects, but needs more research on long-term effects.
63 citations
,
July 2024 in “Journal of the American Academy of Dermatology” Deuruxolitinib effectively promotes hair regrowth in adults with alopecia areata.